Thursday, August 11, 2022


EpicentRx Publishes Commentary in International Journal of Infectious Disease (IJID) on Need for a “Universal” Coronavirus Vaccine to be More Effective Against Novel Viral Variants

Latest Posts

New Study Highlights Superior Efficacy of At-home Dry EEG assessment Compared to Lab-based Monitoring

Results indicate that easy-to-use task-driven EEG can yield clinical-grade data in large-scale, real-world investigations in neuroscience with extremely high adherence rates.

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

“We are excited to further advance the development of GDA-201, a NAM-enabled natural killer (NK) cell therapy candidate which we believe has the potential to be a new readily available, cryopreserved treatment option for cancer patients with relapsed/refractory lymphoma,” said Ronit Simantov, M.D., chief medical and scientific officer of Gamida Cell.

Akadeum Life Sciences Announces New Dead Cell Removal Kit Using Microbubble Technology

Akadeum Life Sciences advises that the new buoyant separation method creates a more effective way for researchers to use valuable samples with a higher retention rate of viable cells than current magnetic techniques.

Bio-Rad Extends Range of StarBright Violet and UltraViolet Dyes for Multiplex Flow Cytometry

StarBright Violet 760, StarBright UltraViolet 575, and StarBright UltraViolet 605 dyes conjugated to highly validated antibodies for multicolor panel design in immunology research.

EpicentRx Inc. (“EpicentRx”), a late-stage biopharmaceutical company developing platforms that treat and target multiple immune-mediated disorders, has published a commentary in one of the top infectious disease journals, International Journal of Infectious Disease (IJID), emphasizing the importance of a “universal” coronavirus vaccine based on the nucleocapsid or N protein instead of the spike or S protein, which is used in current COVID vaccines. The commentary is authored by Bryan Oronsky, Chris Larson, Scott Caroen, Farah Hedjran, Ana Sanchez, and Tony Reid, all of EpicentRx. (click on link to read: IJID nucleocapsid commentary).

The authors point to the N-protein, as an internal RNA-binding protein, as being more essential to viral survival than the S protein, and much more stable and less likely to mutate. Based on this fact, the authors contend that an N-based vaccine would be useful not only against the new COVID-19 variants that continue to appear with regularity but also possibly against all coronaviruses, present or future, since nucleocapsid is a highly conserved or shared coronavirus protein with the potential to establish broad protective immunity.

According to viral immunologist and EpicentRx CEO, Dr. Tony R. Reid, “We’ve already faced three coronavirus pandemics, starting with SARS CoV-1, then MERS, and now SARS-CoV-2 or COVID-19. There have been reports of potential future pandemics due to new variants, which means we need to be ready for the ever-present possibility of ongoing mutation of the virus, especially within the spike protein, as the virus circulates in the population, or the potential for future transmission from animals to humans. If you look at the first SARS-CoV-1 patients, even now they still have T-cells, which recognize the SARS N-protein, and this potentially immunizes them against other coronaviruses. That’s why we made a nucleocapsid targeting vaccine.”

This vaccine was developed from EpicentRx’s adenovirus vaccine platform called AdAPT. The adenovirus, an agent of the common cold, has been modified to carry different genes, which in the case of the EpicentRx vaccine, is nucleocapsid. When the vaccine is injected, it makes many copies of itself, and the nucleocapsid gene that it carries, in the capacity of a “biologic factory” for high level production of nucleocapsid inside the body. The first AdAPT clinical candidate and immediate predecessor of this vaccine is called AdAPT-001, currently in a Phase 1 trial for the treatment of cancer (BETA PRIME; Identifier: NCT04673942). AdAPT-001 carries a gene that traps or neutralizes a protein called transforming growth factor-beta (TGF-beta), which helps tumors to grow.

The EpicentRx vaccine was made “in house” at its own Good Manufacturing Practice (GMP) Production Facility, which is a departure from the usual pharmaceutical model of outsourcing contract manufacturing to third party companies. Based on its experience with AdAPT-001, EpicentRx moved rapidly on design and manufacture of the vaccine for a Phase 1 clinical trial. As Dr. Reid explained, “This is the time for chess, not checkers. If we don’t plan ahead, we’ll be chasing this virus from behind”.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine